Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189122 · ClinicalTrials.gov registry record · NA
Comparative Effects of Aspirin and NHP-544C
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT02189122 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 61 participants.
The verdict
NCT02189122, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
The investigators will compare the effects of rapid release aspirin and NHP-544C on the prostacyclin response to intravenous bradykinin.
Interventions
- DRUG Aspirin 162 mg
- DRUG Aspirin 81 mg
- DRUG Bradykinin
- DRUG NHP544-C 81 mg
- DRUG NHP544C 162 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02189122
The ClinicalTrials.gov registry entry for NCT02189122 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aspirin 162 mg is the first listed.
NCT02189122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02189122 about?
NCT02189122 is a clinical study titled "Comparative Effects of Aspirin and NHP-544C". The investigators will compare the effects of rapid release aspirin and NHP-544C on the prostacyclin response to intravenous bradykinin.
What is the current status of trial NCT02189122?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2014-07. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02189122?
The interventions under investigation include: Aspirin 162 mg (DRUG), Aspirin 81 mg (DRUG), Bradykinin (DRUG), NHP544-C 81 mg (DRUG), NHP544C 162 mg (DRUG).
Who is sponsoring clinical trial NCT02189122?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.